Odyssey Health (ODYY) Free Cash Flow Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 9.73% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -109.40% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 133.09% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 363.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 108.16% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 29.12% |
| 10 | Odyssey Health | - | - | - | -508.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -508.98% |
| Oct 31, 2025 | -14.28% |
| Jul 31, 2025 | 24.26% |
| Apr 30, 2025 | 97.83% |
| Jan 31, 2025 | 94.86% |
| Oct 31, 2024 | -314.83% |
| Jul 31, 2024 | 46.90% |
| Apr 30, 2024 | -10.76% |
| Jan 31, 2024 | -0.40% |
| Oct 31, 2023 | 79.54% |
| Jul 31, 2023 | -111.10% |
| Apr 30, 2023 | 82.86% |
| Jan 31, 2023 | -115.43% |
| Oct 31, 2022 | 74.88% |
| Jul 31, 2022 | 251.16% |
| Apr 30, 2022 | 47.48% |
| Jan 31, 2022 | -34.95% |
| Oct 31, 2021 | -283.93% |
| Jul 31, 2021 | -131.48% |
| Apr 30, 2021 | -6,971.36% |
| Jan 31, 2021 | -212.28% |
| Oct 31, 2020 | -41.31% |
| Jul 31, 2020 | -444.19% |
| Apr 30, 2020 | 11.02% |
| Jan 31, 2020 | -26,378.99% |
| Oct 31, 2019 | -1,068.21% |
| Jul 31, 2019 | -13.39% |
| Apr 30, 2019 | -878.37% |
| Jan 31, 2019 | 99.39% |
| Oct 31, 2018 | 41.93% |
| Jul 31, 2018 | -34.93% |
| Apr 30, 2018 | 96.85% |
| Jan 31, 2018 | -454.58% |
| Oct 31, 2017 | -1,915.21% |
| Jul 31, 2017 | -292.80% |
| Apr 30, 2017 | -361.89% |
| Jan 31, 2017 | 254.01% |
| Oct 31, 2016 | 91.97% |
| Jul 31, 2016 | -920.43% |
| Apr 30, 2016 | -528.06% |
| Jan 31, 2016 | -118.54% |
| Oct 31, 2015 | -116.12% |